Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Breast Cancer: early-phase trial registry
74 of 140 indexed Metastatic Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #82 of 28,707 conditions by registered trial count.
140 US clinical trials · 74 currently recruiting · #82 of 28,707 conditions by registered trial count
Metastatic Breast Cancer: 140 US clinical trials tracked, 74 recruiting.
Metastatic Breast Cancer is the subject of 140 registered US clinical trials on ClinicalTrials.gov, 74 of them currently open to new participants. 11 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 12 of these trials.
Enrollment posture brief
Registry condition metastatic-breast-cancer
OPEN 74 | RECR 53% | LATE 11 | EARLY 99 | RANK #82 | SPON 12
Volume-matched condition peers
Nearest open-share peer: Solid Tumor (53% recruiting · 197 trials)
Metastatic Breast Cancer lists 74 open slots (53% of 140 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Breast Cancer is recruiting above its size-band peers.
74 of 140 indexed trials (52.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Metastatic Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 12 of 140 trials (8.6%). 93 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Breast Cancer enrolment sits around 71 participants.
Median target enrolment is 71 among the 140 trials that report a genuine target (sentinel values excluded). 78 of those (55.7%) plan for fewer than 100 participants.
-
Metastatic Breast Cancer research is mostly interventional.
128 interventional and 12 observational studies make up this index (91.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
140 total, page 3 of 3
PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
Massachusetts General Hospital
NCT03362060
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
RayzeBio
NCT06590857
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05090358
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
HealthPartners Institute
NCT06083038
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Memorial Sloan Kettering Cancer Center
NCT05892068
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
AbbVie
NCT02163694
Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
OBI Pharma
NCT01516307
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
Dompé Farmaceutici S.p.A
NCT02370238
Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy
Novartis Pharmaceuticals
NCT06619704
Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer
R-Pharm
NCT00593827
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
PrECOG
NCT01797120
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
SCRI Development Innovations
NCT01401959
Palliative and Oncology Care Model in Breast Cancer
Massachusetts General Hospital
NCT02730858
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT01576666
A Phase II Trial of Abraxane™ Given Weekly as a Single Agent in First-line Treatment of Metastatic Breast Cancer
Veeda Oncology
NCT00251472
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
SCRI Development Innovations
NCT00894504
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Otto Metzger, MD
NCT02390427
Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
AstraZeneca
NCT07008963
Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)
Loyola University
NCT02186015
Nurse AMIE for Echo Show: Randomized Control Trial
Milton S. Hershey Medical Center
NCT04673019
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Accelerated Community Oncology Research Network
NCT00534417
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
Relay Therapeutics
NCT05759949
A Study of LY2523355 in Participants With Breast Cancer
Eli Lilly and Company
NCT01416389
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Pfizer
NCT05141708
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
Dompé Farmaceutici S.p.A
NCT02001974
IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01939847
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
University of Alabama at Birmingham
NCT00240071
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
Side-Out Foundation
NCT03195192
Aerobic Training in Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT01725633
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
Hoosier Cancer Research Network
NCT00216021
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer
Jenny C. Chang, MD
NCT02073916
Intensive Combo Chemo With Autologous BM Rescue for Metastatic Breast Cancer
University of Oklahoma
NCT00584766
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Merrimack Pharmaceuticals
NCT00911898
ER Reactivation Therapy for Breast Cancer
Dartmouth-Hitchcock Medical Center
NCT02188745
Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Tracon Pharmaceuticals
NCT01326481
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Columbia University
NCT02632071
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
NCT03807765
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
NCT03685331
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Case Comprehensive Cancer Center
NCT02581839
cMet CAR RNA T Cells Targeting Breast Cancer
University of Pennsylvania
NCT01837602
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 52 |
| Phase 3 | 10 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Breast Cancer page
140 registered trials, 74 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 74 Metastatic Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Metastatic Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Breast Cancer condition card totals 140 registered trials; most-linked intervention Fulvestrant; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.